Release date- 22082019 - Bagsvaerd - Novo Nordisk today announced that the European Commission has granted an extension of the indication for Fiasp
(fast-acting insulin aspart), approving it for the treatment of diabetes in adolescents and children (aged one year and above).
Mads Krogsgaard Thomsen, executive vice president & chief science officer at Novo Nordisk, said: "We are very pleased with the decision of the European Commission to expand the indication of Fiasp
, making it available within this younger population.
was approved as a new fast-acting mealtime insulin for the treatment of diabetes.
is a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.
Healthcare company Novo Nordisk revealed on Friday the receipt of approval from the US Food and Drug Administration (FDA) for Fiasp
(insulin aspart injection) in 100 units/ml for the management of type 1 and type 2 diabetes.
Healthcare company Novo Nordisk Canada Inc reported on Monday the launch of Fiasp
(insulin aspart) in Canada as a new treatment option for achieving optimal mealtime glucose control in diabetic patients in the country.
livery of yellow and dark blue will be on the No.
, we've built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target," said Bruce Bode, MD FACE, president of Atlanta Diabetes Associates and Associate Professor at Emory University School of Medicine.
Novo Nordisk, a Danish multinational pharmaceutical company, announced yesterday that Fiasp
, a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada.
Patients who have been prescribed both these medicines should be careful to avoid mixing them up and healthcare professionals should make patients aware of the risk, particularly during the time while yellow Fiasp
products are still available.
medicine: Novorapid 100 u / ml, Novorapid penfill 100 u / ml, Actrapid penfill 100 iu / ml, Insulatard penfill 100 iu / ml, Levemir 100 u / ml (flexpen), Levemir 100 u / ml (penfill), Novomix 30 flexpen 100 u / ml, Novomix 30 penfill 100 u / ml, Mixtard 30 penfill 100 iu / ml, Fiasp
100 units / ml injections.
M2 PHARMA-March 28, 2017-Novo Nordisk's Fiasp
mealtime insulin launched in Canada